Interferons were first described in 1957, but it was not until 34years after their discovery that sufficient quantities of it wereavailable for treatment of hepatitis C virus (HCV) infections,Clinicians now have an excellent understanding of the basis forthe effectiveness of interferon alpha (IFN-α) in the therapy ofthis disease. Here, IFNA1 is linked to glycogen storage disease VI.